Evidence map›Paper›PMID 38031125›Full record

Trial reportRadiation oncology (London, England)2023

Quality assurance in a phase III, multicenter, randomized trial of POstmastectomy radioThErapy in Node posiTive breast cancer with or without Internal mAmmary nodaL irradiation (POTENTIAL): a planning benchmark case.

Yu-Chun Song, Zhi-Hui Hu, Xue-Na Yan, Hui Fang, Yu Tang, Hao Jing, Kuo Men, Na Zhang, Jun Zhang, Jing Jin and 14 more

Open access · goldAbstract readRandomized Controlled TrialMulticenter Study
In one paragraph

Trial report in Radiation oncology (London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 16 institutions in 3 countries.

Yu-Chun Song *Department of Radiation Oncology, National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 Pan jia yuan nan li, Chaoyang District, Beijing, 100021, China.
Zhi-Hui Hu *Department of Radiation Oncology, National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 Pan jia yuan nan li, Chaoyang District, Beijing, 100021, China.
Xue-Na Yan *Department of Radiation Oncology, National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 Pan jia yuan nan li, Chaoyang District, Beijing, 100021, China.
Hui FangDepartment of Radiation Oncology, National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 Pan jia yuan nan li, Chaoyang District, Beijing, 100021, China.
Yu TangDepartment of Radiation Oncology, National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 Pan jia yuan nan li, Chaoyang District, Beijing, 100021, China.
Hao JingDepartment of Radiation Oncology, National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 Pan jia yuan nan li, Chaoyang District, Beijing, 100021, China.
Kuo MenDepartment of Radiation Oncology, National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 Pan jia yuan nan li, Chaoyang District, Beijing, 100021, China.
Na ZhangDepartment of Radiation Oncology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, China.
Jun ZhangDepartment of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Jing JinDepartment of Radiation Oncology, National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital &Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China.
Qiu-Zi ZhongDepartment of Radiation Oncology, Beijing Hospital, Ministry of Health, Beijing, China.
Jun MaDepartment of Radiation Oncology, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
Wei-Fang YangDepartment of Radiation Oncology, Affiliated Taizhou Hospital of Wenzhou Medical University, Taizhou, China.
Ya-Hua ZhongDepartment of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Wuhan, China.
Li-Hua DongDepartment of Radiation Oncology, The First Hospital of Jilin University, Changchun, China.
Xiao-Hong WangDepartment of Radiochemotherapy, Tangshan People's Hospital, Tangshan, China.
Hong-Fen WuDepartment of Radiation Oncology, Cancer Hospital of Jilin Province, Changchun, China.
Xiang-Hui DuDepartment of Radiation Therapy, Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, Zhejiang Province, China.
Xiao-Rong HouDepartment of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100005, China. hxr_pumch@163.com.
Jian TieKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing, 100048, China. tie@yeah.net.
Yu-Fei LuDepartment of Radiation Oncology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, 450003, China. lyf890@sina.com.
Li-Na ZhaoDepartment of Radiation Oncology, Xijing Hospital, The First Affiliated Hospital of Fourth Military Medical University, Xi'an, 710032, China. linazhao1@qq.com.
Ye-Xiong LiDepartment of Radiation Oncology, National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 Pan jia yuan nan li, Chaoyang District, Beijing, 100021, China. yexiong12@163.com.
Shu-Lian WangDepartment of Radiation Oncology, National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 Pan jia yuan nan li, Chaoyang District, Beijing, 100021, China. wangsl@cicams.ac.cn.
Chinese Academy of Medical Sciences & Peking Union Medical College · CNAir Force Medical University · CNBeijing Hospital · CNFirst Hospital of Jilin University · CNFourth Hospital of Hebei Medical University · CNJilin Province Tumor Hospital · CNLiaoning Cancer Hospital & Institute · CNNanjing University of Chinese Medicine · CNNational Cancer Center · USPeking Union Medical College Hospital · CNPeking University Cancer Hospital · CNTangshan People's Hospital · CNWenzhou Medical University · CNZhejiang Cancer Hospital · CNZhengzhou University · CNZhongnan Hospital of Wuhan University · CN

Funding

the Beijing Hope Run Special Fund of Cancer Foundation of China LC2019L02the CAMS Innovation Fund for Medical Sciences 2020-I2M-C&T-B-075
6 · The paper itself

Abstract

purposeTo report the planning benchmark case results of the POTENTIAL trial-a multicenter, randomized, phase 3 trial-to evaluate the value of internal mammary nodal (IMN) irradiation for patients with high-risk breast cancer.

methodsAll participating institutions were provided the outlines of one benchmark case, and they generated radiation therapy plans per protocol. The plans were evaluated by a quality assurance team, after which the institutions resubmitted their revised plans. The information on beams arrangement, skin flash, inhomogeneity corrections, and protocol compliance was assessed in the first and final submission.

resultsThe plans from 26 institutions were analyzed. Some major deviations were found in the first submission. The protocol compliance rates of dose coverage for the planning target volume of chest wall, supraclavicular fossa plus axilla, and IMN region (PTVim) were all significantly improved in the final submission, which were 96.2% vs. 69.2%, 100% vs. 76.9%, and 88.4% vs. 53.8%, respectively. For OARs, the compliance rates of heart D

conclusionThe major deviations were corrected and protocol compliance was significantly improved after revision, which highlighted the importance of planning benchmark case to guarantee the planning quality for multicenter trials.

Indexed as

Breast NeoplasmsRadiotherapy, Intensity-ModulatedBenchmarkingFemaleHumansMastectomyOrgans at RiskRadiotherapy DosageRadiotherapy Planning, Computer-AssistedBenchmark caseBreast cancerInternal mammary nodal irradiationMulticenter trialQuality assuranceRadiation therapy

Identifiers

PMID38031125
PMCPMC10685528
OpenAlexW4389147108

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.